Literature DB >> 24871579

Prevention of hypoxic pulmonary hypertension by hypoxia-inducible expression of p27 in pulmonary artery smooth muscle cells.

Y Luo1, B Zhang2, H-Y Dong2, Y Liu2, Z-C Li2, M-Q Dong2, Y-Q Gao3.   

Abstract

Hypoxia-induced proliferation of pulmonary artery smooth muscle cells (SMCs) is important in the development of hypoxic pulmonary hypertension (HPH). We constructed a lentivirial vector containing a smooth muscle-specific promoter and six copies of hypoxia response element to co-drive the expression of p27, the key cyclin-dependent kinase inhibitor that blocks the G1 to S phase transition in cell cycle progression, in pulmonary artery SMCs in hypoxia. Then in vivo we examined the prevention effects of the vector on HPH in mice and in vitro the specificity on the hypoxia-inducible expression of p27 in pulmonary artery SMCs. Hypobaric hypoxia for 4 weeks resulted in significant increases in the right ventricular systolic pressure, the ratio of right ventricle to left ventricle plus septal weight and the muscularization of pulmonary vessels in mice. Administration of the vector before hypoxia significantly prevented the effects of hypoxia. In vitro, the vector exhibited hypoxic inducibility and relatively specific expression in pulmonary artery SMCs, inhibited the hypoxia-induced proliferation of pulmonary artery SMCs and arrested more cells at G0/G1 phase. These results demonstrate that the hypoxia-inducible p27 expression prevents the development of HPH in mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24871579     DOI: 10.1038/gt.2014.49

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  6 in total

1.  The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway.

Authors:  Weimin Yu; Gang Xu; Hui Chen; Li Xiao; Gang Liu; Pingping Hu; Siqi Li; Vivi Kasim; Chunyu Zeng; Xiaoyong Tong
Journal:  Acta Pharm Sin B       Date:  2022-01-05       Impact factor: 14.903

2.  Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.

Authors:  Ana García-Álvarez; Daniel Pereda; Inés García-Lunar; David Sanz-Rosa; Rodrigo Fernández-Jiménez; Jaime García-Prieto; Mario Nuño-Ayala; Federico Sierra; Evelyn Santiago; Elena Sandoval; Paula Campelos; Jaume Agüero; Gonzalo Pizarro; Víctor I Peinado; Leticia Fernández-Friera; José M García-Ruiz; Joan A Barberá; Manuel Castellá; Manel Sabaté; Valentín Fuster; Borja Ibañez
Journal:  Basic Res Cardiol       Date:  2016-06-21       Impact factor: 17.165

Review 3.  Resveratrol as a potential therapeutic drug for respiratory system diseases.

Authors:  Xiao-Dan Zhu; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Drug Des Devel Ther       Date:  2017-12-15       Impact factor: 4.162

4.  Reversal of Hypoxic Pulmonary Hypertension by Hypoxia-Inducible Overexpression of Angiotensin-(1-7) in Pulmonary Endothelial Cells.

Authors:  Man-Ling Liu; Shu-Juan Xing; Xiao-Qing Liang; Ying Luo; Bo Zhang; Zhi-Chao Li; Ming-Qing Dong
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

5.  Participation of PLK1 and FOXM1 in the hyperplastic proliferation of pulmonary artery smooth muscle cells in pulmonary arterial hypertension.

Authors:  Jamie L Wilson; Lizhen Wang; Zeyu Zhang; Nicholas S Hill; Peter Polgar
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

Review 6.  NSFC spurs significant basic research progress of respiratory medicine in China.

Authors:  Ruijuan Sun; Feng Xu; Chen Wang; Erdan Dong
Journal:  Clin Respir J       Date:  2015-08-12       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.